Rebecca Byam

CFO Rebecca Byam buys 14,235 shares at $1.40 in HCWB private placement; prior cross-ticker buys averaged -76.8% 30d return, 0 win rate.

Rebecca Byam, CFO of HCW Biologics Inc., purchased 14,235 shares at $1.40 on 2026-05-22 through a private placement (not a discretionary open-market buy), increasing her holdings by 33.1% to 57,245 shares post-transaction. This transaction cannot be interpreted as a buying signal driven by insider conviction, given the private-placement structure flagged in the filing. Her cross-ticker track record across 7 prior open-market buys shows an average 30-day return of -76.8% and average 90-day return of -82.6%, with a 0.00% 90-day win rate, suggesting a pattern of poorly timed purchases historically. The current stock price of $1.94 sits 78.0% below the 52-week high and has surged 341.9% over the past 30 days from a depressed base, but this price recovery does not align with her prior execution outcomes at the company. Finally, the company reported annual revenue growth of -97.9% and was unprofitable over its most recent full fiscal year, creating a fundamental backdrop of significant business contraction that warrants monitoring of whether the private placement reflects capital needs or strategic repositioning.

CFO Rebecca Byam buys 8,462 shares of HCWB at $26.00 on 2025-05-08; stock now $6.18, down 87.5% from 52-week high, amid cluster buying by 5 other insiders.

Byam purchased 8,462 shares at $26.00, increasing her holdings by 24.5% to 43,010 shares post-transaction, concurrent with a cluster of 5 other insider buys within 14 days. Her prior trades at HCWB (5 purchases in September 2023) each achieved 90-day returns ranging from +1997.2% to +2158.3%, establishing a pattern of well-timed entries at this ticker. However, the current purchase occurs at a severe valuation cliff: the stock now trades at $6.18, representing a 87.5% decline from its 52-week high of $49.60 and a 35.4% drop over the past 30 days. The company is unprofitable (net income $-3,902,288.00 in the latest quarter), reports declining annual revenue (-9.7%), and operates with a market cap of $277,692,861.60 against quarterly revenue of only $426,423.00. This combination—a historically accurate insider accumulating heavily while the stock crashes and fundamentals deteriorate—creates ambiguity: the timing pattern at HCWB historically favored buys, yet the present price action and negative earnings fundamentals present material headwinds that differ from the September 2023 context.